Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
BRISBANE, Calif., Aug. 15, 2017 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, PhD., Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in four upcoming investor conferences.
Piper Jaffray Bus Tour in Palo Alto, CA
- Dr. Peter Maag and Michael Bell will participate on Wednesday, August 23, 2017
at 9:30am PT/12:30pm ET
Southern California Investor Conference in Newport Beach, CA
- Dr. Peter Maag will present on Thursday, August 24, 2017 at 10:30am PT/1:30pm ET
Rodman & Renshaw 19th Annual Global Investment Conference in New York City
- Dr. Peter Maag will present on Monday, September 11, 2017 at 12:00pm PT/3:00pm ET
Cantor Fitzgerald Global Healthcare Conference in New York City
- Dr. Peter Maag will present on Tuesday, September 26, 2017 at 12:25pm PT/3:25pm ET
Live audio webcasts of Southern California Investor, Rodman & Renshaw Global Investment and Cantor Fitzgerald Global Health conferences will be available online from the investor relations page of the Company's website at http://investors.caredxinc.com. The webcast replays of the presentations will begin approximately one hour after the conclusion of the live presentations and will be available on the Company's website for 90 days. Due to the one-on-one only format of the Piper Jaffray Bus Tour, no webcast will be available.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Investor Contact Sasha King, Chief Commercial Officer T: +1 415-287-2393 E: [email protected]
